MX370597B - Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. - Google Patents

Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.

Info

Publication number
MX370597B
MX370597B MX2015010372A MX2015010372A MX370597B MX 370597 B MX370597 B MX 370597B MX 2015010372 A MX2015010372 A MX 2015010372A MX 2015010372 A MX2015010372 A MX 2015010372A MX 370597 B MX370597 B MX 370597B
Authority
MX
Mexico
Prior art keywords
cancer
therapeutic
binding reagents
diagnostic target
dll3 binding
Prior art date
Application number
MX2015010372A
Other languages
English (en)
Spanish (es)
Other versions
MX2015010372A (es
Inventor
Jane Hudson Lindsey
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47998983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370597(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2015010372A publication Critical patent/MX2015010372A/es
Publication of MX370597B publication Critical patent/MX370597B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015010372A 2013-02-12 2014-02-12 Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. MX370597B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1302447.6A GB201302447D0 (en) 2013-02-12 2013-02-12 Therapeutic and diagnostic target
PCT/GB2014/050407 WO2014125273A1 (en) 2013-02-12 2014-02-12 Therapeutic and diagnostic target for cancer comprising dll3 binding reagents

Publications (2)

Publication Number Publication Date
MX2015010372A MX2015010372A (es) 2015-10-29
MX370597B true MX370597B (es) 2019-12-18

Family

ID=47998983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010372A MX370597B (es) 2013-02-12 2014-02-12 Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.

Country Status (18)

Country Link
US (3) US20160032006A1 (enExample)
EP (2) EP2956483B1 (enExample)
JP (1) JP6654046B2 (enExample)
KR (1) KR102167550B1 (enExample)
CN (1) CN105143266B (enExample)
AU (1) AU2014217611B2 (enExample)
CA (1) CA2900134A1 (enExample)
CL (1) CL2015002223A1 (enExample)
DK (1) DK2956483T3 (enExample)
EA (1) EA034182B1 (enExample)
ES (1) ES2813360T3 (enExample)
GB (1) GB201302447D0 (enExample)
HU (1) HUE050828T2 (enExample)
IL (1) IL239983B (enExample)
MX (1) MX370597B (enExample)
PH (1) PH12015501744A1 (enExample)
PL (1) PL2956483T3 (enExample)
WO (1) WO2014125273A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812849T3 (es) 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
AU2014312210A1 (en) * 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Engineered anti-DLL3 conjugates and methods of use
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
EA201691683A1 (ru) 2014-02-21 2017-04-28 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
CA2956471C (en) 2014-07-31 2024-09-10 Amgen Res Munich Gmbh OPTIMIZED CONSTRUCTIONS OF SINGLE-CATENAL, BI-SPECIFIC, AND CROSS-SPECIFIC ANTIBODY
AR101400A1 (es) * 2014-07-31 2016-12-14 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
LT3411404T (lt) 2016-02-03 2022-12-27 Amgen Research (Munich) Gmbh Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
EA039325B1 (ru) * 2016-02-03 2022-01-13 Эмджен Рисерч (Мюник) Гмбх Конструкции биспецифических антител, связывающиеся с дпб3 (dll3) и кд3 (cd3)
CN110997722B (zh) 2017-06-08 2023-09-26 黑带医疗有限公司 Cd38调节抗体
CN111032693B (zh) 2017-08-16 2023-09-26 黑带医疗有限公司 Cd38调节抗体
CA3072296A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 antibody
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
TW201938194A (zh) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 包含結合cd3及cd137的改變的抗體可變區之抗原結合分子
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
CN110412179A (zh) * 2018-04-26 2019-11-05 缪荣明 一种液相色谱检测颗粒酶a的方法
AU2019267349B2 (en) 2018-05-08 2025-06-05 Phanes Therapeutics, Inc. Anti-DLL3 antibodies and uses thereof
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN112789294A (zh) 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CA3115089A1 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
CN119661722A (zh) 2019-02-21 2025-03-21 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
EP3927747A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN113874526A (zh) * 2019-03-08 2021-12-31 肿瘤实验室诊断有限公司 癌症的诊断和预后
CA3132202A1 (en) * 2019-04-08 2020-10-15 Phanes Therapeutics, Inc. Humanized anti-dll3 chimeric antigen receptors and uses thereof
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
CN115643806A (zh) * 2020-01-31 2023-01-24 璟尚生物制药公司 双特异性t细胞接合器
US12486331B2 (en) 2020-01-31 2025-12-02 Gensun Biopharma Inc. Bispecific T cell engagers
PH12022500013A1 (en) 2020-03-31 2023-09-11 Chugai Pharmaceutical Co Ltd Dll3-targeting multispecific antigen-binding molecules and uses thereof
AU2022217274A1 (en) * 2021-02-05 2023-07-27 Phanes Therapeutics, Inc. Bispecific antibodies with charge pairs and uses thereof
IL311510A (en) * 2021-09-17 2024-05-01 Wuxi Biologics Ireland Ltd D3 binding molecules and uses thereof
EP4519294A1 (en) * 2022-05-04 2025-03-12 Earli Inc. Methods using surface-expressable activatable epitopes to localize and/or treat diseased cells
TW202530259A (zh) * 2023-09-21 2025-08-01 大陸商樂普創一生物科技（上海）有限公司 抗ｄｌｌ３抗體及其用途
WO2025190281A1 (en) * 2024-03-11 2025-09-18 Lepu Biopharma Co., Ltd. Anti-dll3 antibodies and uses thereof
CN119841904A (zh) * 2025-03-18 2025-04-18 中国科学院近代物理研究所 一种dll3亲和肽及其应用
CN120168667A (zh) * 2025-03-18 2025-06-20 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
GB9106048D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
AU8874591A (en) 1990-10-22 1992-05-20 Abbott Laboratories Stabilized anoxic diagnostic reagent solution
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JP3949712B2 (ja) 1991-12-02 2007-07-25 メディカル リサーチ カウンシル 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE69333366T2 (de) 1992-10-30 2004-09-16 The General Hospital Corp., Boston Ein neues zellzyklus kontrollprotein
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9608510D0 (en) 1996-04-25 1996-07-03 Medical Res Council Calcium dependent binding ligands
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20060223114A1 (en) 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
PT1390535E (pt) 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US6989452B2 (en) 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
EP2357237A1 (en) 2003-05-14 2011-08-17 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
CA2523716C (en) 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
WO2006055689A2 (en) 2004-11-16 2006-05-26 Avidia Research Institute Protein scaffolds and uses thereof
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP2009523709A (ja) * 2005-12-16 2009-06-25 ジェネンテック・インコーポレーテッド 神経膠腫の診断、予後の予測及び治療の方法
WO2007080597A2 (en) 2006-01-16 2007-07-19 Compugen Ltd. Polynucleotide and polypeptide sequences and methods for diagnosis
EP2079483A4 (en) * 2006-07-29 2010-10-20 Robert Lamar Bjork Jr BISPECIFIC MONOCLONAL ANTIBODIES (SPECIFIC FOR CD3 AND CD11B) THERAPEUTIC MEDICAMENTS
PT2155783E (pt) 2007-04-03 2013-11-07 Amgen Res Munich Gmbh Domínio de ligação específico inter-espécies
US8540998B2 (en) 2007-12-24 2013-09-24 Oxford Biotherapeutics Ltd. Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
WO2009124931A2 (en) * 2008-04-07 2009-10-15 Ablynx Nv Amino acid sequences directed against the notch pathways and uses thereof
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
JP2013505223A (ja) 2009-09-18 2013-02-14 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー ＥｐＣＡＭｘＣＤ３二重特異性抗体を投与するための投与計画
DK3342786T3 (en) 2010-01-29 2021-09-27 Chugai Pharmaceutical Co Ltd Anti-dll3-antistof
US9002545B2 (en) 2011-01-07 2015-04-07 Wabtec Holding Corp. Data improvement system and method
JP2014514314A (ja) * 2011-04-20 2014-06-19 ゲンマブ エー／エス Ｈｅｒ２およびｃｄ３に対する二重特異性抗体
ME03440B (me) 2011-05-21 2020-01-20 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
ES2812849T3 (es) * 2012-02-24 2021-03-18 Abbvie Stemcentrx Llc Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos

Also Published As

Publication number Publication date
GB201302447D0 (en) 2013-03-27
CN105143266B (zh) 2021-08-13
KR20150119164A (ko) 2015-10-23
EP3736293A1 (en) 2020-11-11
IL239983A0 (en) 2015-09-24
CN105143266A (zh) 2015-12-09
EA201500835A1 (ru) 2016-02-29
US20210079114A1 (en) 2021-03-18
CA2900134A1 (en) 2014-08-21
EP2956483A1 (en) 2015-12-23
DK2956483T3 (da) 2020-08-10
ES2813360T3 (es) 2021-03-23
US20180201691A1 (en) 2018-07-19
HUE050828T2 (hu) 2021-01-28
AU2014217611A1 (en) 2015-08-06
EP2956483B1 (en) 2020-05-27
PH12015501744A1 (en) 2015-12-07
NZ710248A (en) 2021-03-26
JP6654046B2 (ja) 2020-02-26
AU2014217611B2 (en) 2018-05-17
IL239983B (en) 2021-02-28
US20160032006A1 (en) 2016-02-04
PL2956483T3 (pl) 2020-11-30
PH12015501744B1 (en) 2002-06-26
KR102167550B1 (ko) 2020-10-19
MX2015010372A (es) 2015-10-29
CL2015002223A1 (es) 2016-04-29
EA034182B1 (ru) 2020-01-15
JP2016513094A (ja) 2016-05-12
WO2014125273A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
HUS2400024I1 (hu) A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
EP4356960A3 (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
MX370818B (es) Anticuerpos anti-b7-h1 para tratar tumores.
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
EA201300171A1 (ru) Способы и композиции для терапии рака печени
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
HK1214611A1 (zh) 作为癌症治疗和诊断靶标的ly75
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
MX2018001831A (es) Biomarcadores para el tratamiento de alopecia areata.
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
WO2015001013A3 (en) Human anti-ifn-alpha antibodies
EP3292218A4 (en) COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, FORECASTING, DETECTION AND TREATMENT OF CANCER
EP3359203C0 (en) RECEPTOR-BINDING DOMAINS LIGANDS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF PANCREAS CANCER
PT2984108T (pt) Anticorpos anti-s100a7 para o tratamento e diagnóstico de cancro
WO2013001369A3 (en) Therapeutic and diagnostic target

Legal Events

Date Code Title Description
FG Grant or registration